New therapy to treat spinal cord injuries shows improvements
A new therapy to treat spinal cord injuries in people who have lost all motor and sensory function below the injury site shows additional motor function improvement at 6-months and 9-months following treatment with 10 million AST-OPC1. The positive efficacy results from an ongoing research study were announced on Jan. 24 in a conference held by Asterias Biotherapeutics, Inc., the biotechnology company that manufactures AST-OPC1.

"With these patients, we are seeing what we believe are meaningful improvements in their ability to use their arms, hands and fingers at six months and nine months following AST-OPC1 administration," said Dr. Richard G. Fessler, professor in the department of neurosurgery at Rush University Medical Center and lead investigator in the SCiStar Phase 1/2a study. Rush is one of six centers in the country currently studying this new approach.
Like
Comment
Share